PharmaCyte Biotech (Formerly Known As Nuvilex)
1971 Old Cuthbert Road
Cherry Hill
New Jersey
08034
United States
Tel: 856-433-6088
Fax: 856-354-1077
Website: http://www.nuvilex.com/
Email: info@nuvilex.com
375 articles about PharmaCyte Biotech (Formerly Known As Nuvilex)
-
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc.
11/15/2023
PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) (“Femasys”), a biomedical company focused on meeting significant unmet needs for women worldwide.
-
Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech
11/15/2023
Femasys Inc. today announced a strategic upfront investment of $6.85 million by public biotech company, PharmaCyte Biotech, Inc. (Nasdaq: PMCB) and other healthcare investors.
-
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology
10/31/2023
PharmaCyte Biotech, Inc. provides an update on its investigation of its Cell-in-a-Box technology and initial next steps in development. Following a comprehensive scientific review of amassed data, the Company is in the process of requesting a meeting with the U.S. Food and Drug Administration for guidance on further development of the technology.
-
PharmaCyte Biotech Announces Final Results of Tender Offer
6/15/2023
PharmaCyte Biotech, Inc. announces the final results of its previously announced tender offer to acquire up to 7,750,000 million shares of the Company’s common stock, par value $0.001 per share, at a price of $3.25 per share in cash, less any applicable withholding taxes and without interest.
-
PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share
5/11/2023
PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) today announces a cash tender offer for up to 7,750,000 shares at $3.25 per share, less any applicable withholding taxes and without interest.
-
PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan
2/2/2023
PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”) announced today that its Board of Directors has authorized a second share repurchase program to repurchase up to $10 million of PharmaCyte’s outstanding common stock.
-
PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder ValueTopics to Include Continued Analysis of FDA’s Clinical Hold on IND for Cell-in-a-Box®
10/7/2022
PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”) announces today that its Board of Directors has empowered its Business Review Committee to evaluate opportunities to realize optimal shareholder value.
-
PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital
8/15/2022
PharmaCyte Biotech, Inc. announced today that PharmaCyte and Iroquois have signed a Cooperation Agreement that includes naming two of Iroquois’ director designees to PharmaCyte’s reconstituted Board of Directors.
-
Iroquois Files Preliminary Consent Materials to Reconstitute Board of Directors at PharmaCyte Biotech, Inc.
7/28/2022
Iroquois Capital Management, LLC announced that it has filed preliminary consent materials with the SEC regarding its solicitation of written consents from stockholders in lieu of a stockholder meeting to reconstitute a majority of the PharmaCyte Board of Directors with its slate of highly qualified nominees.
-
PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study
7/21/2022
PharmaCyte Biotech, Inc. announced today that it has commenced the pilot phase of its two-phase pig study.
-
PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study
7/19/2022
PharmaCyte Biotech, Inc. announced today that it has achieved positive interim results in its study to establish a malignant ascites mouse model which will form the basis for further testing of the effectiveness of its CypsCaps™.
-
PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022
7/11/2022
PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced its preliminary unaudited financial results for fiscal year ended April 30, 2022.
-
IROQUOIS CAPITAL COMMENCES CONSENT SOLICITATION TO RECONSTITUTE PHARMACYTE BIOTECH BOARD OF DIRECTORS
7/11/2022
Iroquois Capital Management, LLC (together with its affiliates, "Iroquois"), announced that on Friday, July 8, 2022 , that it had delivered a written consent to PharmaCyte Biotech, Inc. ("PharmaCyte", "PMCB" or the "Company") (NASDAQ: PMCB) seeking the consent of stockholders to expand the size of PharmaCyte's Board of Directors.
-
PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells
7/5/2022
PharmaCyte Biotech, Inc. today announced the results of a study to determine whether a previous established quantitative real-time PCR ( qRT-PCR) could be used as a quality control test for its CypCaps™ product candidate.
-
PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value
6/15/2022
PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today issued the following statement in response to the second letter issued by Iroquois Capital (Iroquois) on June 9, 2022:
-
PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego
6/13/2022
PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced that its Chief Executive Officer, Kenneth L. Waggoner, will represent PharmaCyte at the 2022 BIO International Convention (BIO).
-
PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value
6/8/2022
PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today issued the following letter to its shareholders in response to the concerns expressed by Iroquois Capital Management (Iroquois) in its letter to the PharmaCyte Board of Directors.
-
PharmaCyte Biotech to Implement $10-Million Share Repurchase Program
6/2/2022
PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced that its Board of Directors (Board) has authorized a share repurchase program to repurchase up to $10 million of PharmaCyte’s outstanding common stock.
-
PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites
5/23/2022
PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that it has initiated the first in a series of studies to test the ability of its pancreatic cancer therapy to treat malignant ascites.
-
PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes
4/27/2022
PharmaCyte Biotech, Inc. (NASDAQ: PMCB), announced today that the management team will be attending the 15th International Conference on Advanced Technologies and Treatments for Diabetes.